Form 8-K - Current report:
SEC Accession No. 0001628280-26-034583
Filing Date
2026-05-13
Accepted
2026-05-13 16:03:30
Documents
13
Period of Report
2026-05-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K allo-20260512.htm   iXBRL 8-K 30491
2 EX-99.1 allo-20260331xexx991q126.htm EX-99.1 55161
6 g725933allogenea06a.jpg GRAPHIC 7772
  Complete submission text file 0001628280-26-034583.txt   225367

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20260512.xsd EX-101.SCH 1870
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20260512_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20260512_pre.xml EX-101.PRE 12595
17 EXTRACTED XBRL INSTANCE DOCUMENT allo-20260512_htm.xml XML 2763
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 26973134
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)